Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.08 USD | -4.42% | -10.74% | -47.06% |
May. 24 | Sector Update: Health Care Stocks Decline Late Friday Afternoon | MT |
May. 24 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.06% | 137M | |
+16.34% | 79.03B | |
+8.65% | 8.78B | |
-16.33% | 4.83B | |
+51.22% | 4.65B | |
+2.18% | 3.89B | |
+20.51% | 2.34B | |
-26.79% | 2.18B | |
+15.12% | 2.11B | |
-36.56% | 2B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023